TOI — The Oncology Institute, Inc.

Summary of The Oncology Institute (TOI) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue Growth: TOI reported Q4 2025 revenue of $142 million, a 41.6% increase year-over-year, and full-year revenue of $502.7 million, up approximately 28% from $393.4 million in 2024.
• Adjusted EBITDA: Achieved positive adjusted EBITDA of $147,000 in Q4 2025, marking the first profitable quarter since going public.
• Gross Profit: Q4 gross profit was $22.7 million, with a gross margin of 16%, up from 14.6% year-over-year.
• Cash Position: Ended the year with $33.6 million in cash and positive operating cash flow of $3.2 million in Q4.

2. Strategic Updates and Business Highlights

• Capitated Care Model Expansion: Initiated 9 new capitated contracts in 2025, adding approximately 260,000 patient lives under management, particularly in Florida, California, and Nevada.
• Part D Dispensing Platform: Pharmacy revenue grew 49.6% year-over-year to $269.2 million, contributing significantly to overall revenue growth.
• Operational Efficiency: SG&A expenses decreased by 2% year-over-year, reflecting improved operational efficiency and cost management.
• Leadership Strengthening: Added key executives to the leadership team to support growth and scalability.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected revenue between $630 million and $650 million, with approximately $150 million expected from capitated contracts.
• Capitated Revenue Growth: Anticipating over 80% growth in capitated revenue for 2026.
• Adjusted EBITDA Guidance: Expected to range from $0 million to $9 million, with free cash flow projected to be negative $15 million to positive $5 million.
• Seasonal Impact: First quarter of 2026 expected to be seasonally low due to patient deductible resets and drug price increases.

4. Bad News, Challenges, or Points of Concern

• Inflation Reduction Act (IRA) Impact: Expected minor unfavorable impact on IMBRUVICA revenue due to price negotiations, though management believes they can mitigate this through operational adjustments.
• Potential Margin Pressure: Transitioning to a larger number of capitated contracts may initially lead to higher medical loss ratios (MLR), particularly in mid-2026.
• Competitive Pressures: The market for oncology care remains competitive, and TOI must navigate pricing pressures and maintain contract terms in a potentially lower rate environment.

5. Notable Q&A Insights

• Dispensing Revenue Drivers: Strong performance attributed to operational execution and increased patient encounters linked to capitated contracts.
• Growth Opportunities: Significant potential for growth in Florida's Medicare Advantage market, with existing contracts expected to expand.
• AI Efficiency Gains: Anticipated savings of $2 million in SG&A from AI-related efficiencies, particularly in prior authorization processes.
• Fee-for-Service Revenue Outlook: Expected to see flat to low single-digit growth due to the cannibalization effect from increased capitated lives, though organic growth from existing markets is anticipated.

Overall, TOI demonstrated strong financial performance in Q4 2025, with significant growth in revenue and the achievement of positive adjusted EBITDA. The company is strategically positioned for further growth in 2026, although it faces challenges related to market competition and potential impacts from regulatory changes.